- Home
- ZVRA vs LXEO Comparison
ZVRA vs LXEO Comparison
Compare ZVRA & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZVRA | LXEO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 486.1M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZVRA | LXEO |
|---|---|---|
| Price | $9.13 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $23.00 | $18.60 |
| AVG Volume (30 Days) | ★ 1.0M | 700.1K |
| Earning Date | 03-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.21 | 75.08 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $106,470,000.00 | $654,000.00 |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $53.42 | N/A |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $6.19 | $1.45 |
| 52 Week High | $13.16 | $10.99 |
Technical Indicators
Market Signals| Indicator | ZVRA | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 34.96 |
| Support Level | $8.33 | $4.67 |
| Resistance Level | $9.44 | $7.77 |
| Average True Range (ATR) | 0.49 | 0.47 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 25.63 | 18.68 |
Price Performance
Historical ComparisonAbout ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.